HCW Biologics Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are to FY2020. This is an annual report, not a standalone fourth-quarter report. HCW Biologics is a development-stage biopharmaceutical company focused on immunotherapies for cancer and age-related inflammatory diseases. It had no approved products and generated no product sales.
Financial performance and liquidity
| Metric | FY2021 / year-end | FY2020 / comparison |
|---|---|---|
| Revenue | $0 | $4.10 million |
| Research and development expense | $8.17 million | $7.26 million |
| General and administrative expense | $5.19 million | $2.67 million |
| Net loss | $12.86 million | $5.80 million |
| Net loss per share, basic and diluted | $0.69 | $1.49 |
| Cash used in operating activities | $10.98 million | $10.43 million |
| Cash and cash equivalents | $11.73 million | $8.46 million |
| Short-term U.S. Treasury investments | $24.98 million | — |
| Long-term investments | $11.52 million, including $9.92 million in Treasury notes and $1.60 million in Wugen shares | $1.60 million |
| Total assets / current liabilities | $53.51 million / $2.32 million | $15.40 million / $1.00 million |
Operating expenses rose 26% year over year, driven by higher preclinical and public-company costs. Net loss widened as FY2020 included $4.10 million of Wugen-license revenue, while FY2021 had none. FY2021 interest and other income of $505,000 included a $567,000 gain from forgiveness of the Paycheck Protection Program loan; the company reported no material outstanding debt at year-end. No operating margin is meaningful given the absence of revenue.
Cash provided by financing was $49.27 million, primarily net IPO proceeds of $49.24 million. Investing activities used $35.02 million, mainly to purchase Treasury securities. Management said existing cash and cash equivalents and investments were expected to fund operations through the end of 2023, based on assumptions that may prove incorrect. Manufacturing commitments were $2.5 million at year-end; the company also disclosed $1.8 million of deferred Wugen supply revenue in current liabilities.
Business developments and changes
- The July 2021 IPO sold 7.0 million shares at $8.00 per share, generating approximately $49.2 million in net proceeds. Preferred stock converted to common stock upon the IPO.
- HCW9218 received FDA clearance in October 2021 for a company-sponsored Phase 1b trial in advanced pancreatic cancer. A University of Minnesota-sponsored Phase 1 trial in advanced solid tumors received FDA clearance in January 2022. Both were expected to begin in the first half of 2022; the filing reports planned timing, not trial outcomes.
- HCW9302 remained in preclinical/IND-enabling development. The company expected to complete enabling work by the end of 2022 and planned an IND submission for a Phase 1b alopecia areata trial, with the filing also describing a possible first-half 2023 submission.
- Research and development expense increased 13%; general and administrative expense increased 95%, including higher compensation, professional services and insurance costs.
- FY2020 revenue came from the Wugen license. Wugen may provide future milestone payments and single-digit royalties, but these depend on development and commercialization outcomes. FY2021 supply payments were deferred pending finalized statements of work and satisfaction of revenue-recognition conditions.
Outlook, commentary and key risks
Management expects substantial operating losses and higher development spending as clinical trials advance, preclinical programs continue, and manufacturing and public-company infrastructure expand. HCW9218 is the lead clinical program; HCW9302 is not yet in clinical testing. The company intends to pursue licensing or collaboration arrangements, but future proceeds are uncertain.
Material risks include clinical failure or delay, patient enrollment and site-startup challenges, FDA and other regulatory uncertainty, reliance on third-party manufacturers and suppliers, COVID-19-related disruption, additional financing needs and potential shareholder dilution. The company relies on outsourced cGMP manufacturing and had no long-term supply arrangements. It also highlighted uncertainty over patent protection, competition, commercialization, reimbursement and whether its novel platform will yield approved products.
The financial statements received an unqualified independent auditor opinion. Management concluded disclosure controls were effective at December 31, 2021; the filing did not include management’s ICFR assessment or an auditor attestation, citing newly public company and emerging-growth-company exemptions. No material legal proceedings were reported.
Important facts for investors to verify
- Whether the two HCW9218 trials actually started on the expected timetable, and subsequent enrollment, safety and dose-escalation progress.
- Completion of HCW9302 IND-enabling studies and the timing and regulatory status of its planned IND submission.
- Cash burn, investment balances and whether management’s runway estimate through 2023 remains supportable as trial and manufacturing costs rise.
- Manufacturing capacity, cGMP lot release, supply-chain resilience and the $2.5 million manufacturing commitment.
- Wugen supply-contract execution and any realized milestones or royalties; the filing does not establish that contingent payments will be earned.
- Financing plans, potential dilution, and progress in securing partnerships or other non-dilutive funding.